Biohaven Shares Drop Following RBC Downgrade
Biohaven Pharmaceutical (NYSE:BHVN) shares declined in premarket trading after RBC Capital downgraded the stock from Outperform to Sector Perform and reduced its price target. The downgrade was attributed primarily to valuation concerns, as Biohaven's share price had risen over 100% since early 2026 lows and nearly 40% year-to-date. RBC also evaluated Biohaven’s Opakalim clinical programme for epilepsy but noted limited patient data and a lack of clear differentiation. The firm acknowledged the recent $400 million licensing deal with SK Biopharmaceuticals, which improved Biohaven's financial position ahead of key Phase 3 results expected soon. Biohaven faces competition from Xenon Pharmaceuticals in the Kv7 channel modulator space for epilepsy treatment. Analysts remain cautious about whether Opakalim can meet peak sales estimates without stronger clinical differentiation.
Topics: Biohaven clinical pipeline price target reduction RBC Capital Markets